The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study.
Ying LiLin DangChengzhi LvBingjiang LinJuan TaoNan YuYa DengHuiping WangXiaojing KangHui QinRong ChenJinnan LiYunsheng LiangYanhua LiangYu-Ling ShiPublished in: Drug safety (2024)
In this real-world study, ixekizumab was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis, with no difference in safety across most patient subgroups.